Literature DB >> 27236779

The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival.

U F Wellner1, YinFeng Shen2, T Keck1, WenYin Jin3, Ze Xu3.   

Abstract

PURPOSE: To assess the available evidence on the prognostic factors for the 5-year survival for patients with distal cholangiocarcinoma (DCC) following surgical resection.
METHODS: We performed a comprehensive search of abstracts included in databases where relevant studies were published between January 2000 and August 2015. Risk ratios (RRs), 95 % confidence intervals (95 % CIs), and random-effects model were calculated using RevMan 5.3 software.
RESULTS: A total of 23 observational studies involving 2063 patients with DCC were analyzed. The meta-analysis showed that postoperative adjuvant chemotherapy was not confirmed as a prognostic factor, with similar 5-year survival rates between those receiving and not receiving chemotherapy (RR 0.71; 95 % CI 0.21-2.36; P = 0.57). Perineural invasion (RR 0.51; 95 % CI 0.40-0.64; P < 0.00001), lymph node metastasis (RR 0.51; 95 % CI 0.38-0.70; P < 0.0001), positive resection margin status (RR 2.11; 95 % CI 1.36-3.30; P = 0.001), and not-well-differentiated adenocarcinoma (RR 1.77; 95 % CI 1.39-2.25; P < 0.00001) were associated with shorter survival.
CONCLUSIONS: Perineural invasion, lymph node metastasis, resection margin status, and tumor differentiation were the significant prognostic factors for the 5-year survival.

Entities:  

Keywords:  Distal cholangiocarcinoma; Meta-analysis; Prognostic factors

Mesh:

Year:  2016        PMID: 27236779     DOI: 10.1007/s00595-016-1362-0

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  30 in total

1.  Prognostic significance of lymph node metastasis and surgical margin status for distal cholangiocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Yasuo Hayashidani; Takeshi Sudo; Yasushi Hashimoto; Hiroki Ohge; Taijiro Sueda
Journal:  J Surg Oncol       Date:  2007-03-01       Impact factor: 3.454

2.  Predictors of Survival in Ampullary, Bile Duct and Duodenal Cancers Following Pancreaticoduodenectomy: a 10-Year Multicentre Analysis.

Authors:  Stéphane Bourgouin; Jacques Ewald; Julien Mancini; Vincent Moutardier; Jean-Robert Delpero; Yves-Patrice Le Treut
Journal:  J Gastrointest Surg       Date:  2015-05-07       Impact factor: 3.452

3.  Adenocarcinoma of the distal bile duct. A clinicopathologic outcome analysis after curative resection.

Authors:  L Bortolasi; L J Burgart; G G Tsiotos; E Luque-De León; M G Sarr
Journal:  Dig Surg       Date:  2000       Impact factor: 2.588

4.  Intrahepatic, peri-hilar and distal cholangiocarcinoma: Three different locations of the same tumor or three different tumors?

Authors:  G Ercolani; A Dazzi; F Giovinazzo; A Ruzzenente; C Bassi; A Guglielmi; A Scarpa; A D'Errico; A D Pinna
Journal:  Eur J Surg Oncol       Date:  2015-06-10       Impact factor: 4.424

5.  Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer.

Authors:  Takanori Yoshida; Toshifumi Matsumoto; Atsushi Sasaki; Yuji Morii; Masanori Aramaki; Seigo Kitano
Journal:  Arch Surg       Date:  2002-01

6.  Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Akira Nakashima; Naru Kondo; Ryutaro Sakabe; Hiroki Ohge; Taijiro Sueda
Journal:  Ann Surg Oncol       Date:  2010-10-14       Impact factor: 5.344

7.  Prognostic impact of lymph node metastasis in distal cholangiocarcinoma.

Authors:  M Kiriyama; T Ebata; T Aoba; Y Kaneoka; T Arai; Y Shimizu; M Nagino
Journal:  Br J Surg       Date:  2015-01-22       Impact factor: 6.939

8.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

Review 9.  Pathogenesis, diagnosis, and management of cholangiocarcinoma.

Authors:  Sumera Rizvi; Gregory J Gores
Journal:  Gastroenterology       Date:  2013-10-15       Impact factor: 22.682

10.  Prognostic factors following surgical resection of distal bile duct cancer.

Authors:  Young Jae Chung; Dong Wook Choi; Seong Ho Choi; Jin Seok Heo; Dong Hun Kim
Journal:  J Korean Surg Soc       Date:  2013-10-25
View more
  22 in total

1.  Survival outcome and prognostic factors after pancreatoduodenectomy for distal bile duct carcinoma: a retrospective multicenter study.

Authors:  Ekaterina Petrova; Felix Rückert; Sebastian Zach; YinFeng Shen; Jürgen Weitz; Robert Grützmann; Uwe A Wittel; Frank Makowiec; Ulrich T Hopt; Peter Bronsert; Florian Kühn; Bettina M Rau; Roman E Izrailov; Igor E Khatkov; Hryhoriy Lapshyn; Louisa Bolm; Dirk Bausch; Tobias Keck; Ulrich F Wellner; Gabriel Seifert
Journal:  Langenbecks Arch Surg       Date:  2017-06-13       Impact factor: 3.445

2.  Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohort.

Authors:  Damien Bergeat; Olivier Turrini; Laetitia Courtin-Tanguy; Stéphanie Truant; Benjamin Darnis; Jean Robert Delpero; Jean-Yves Mabrut; Nicolas Regenet; Laurent Sulpice
Journal:  Langenbecks Arch Surg       Date:  2018-08-15       Impact factor: 3.445

3.  Serum p53 antibody as a potential tumor marker in extrahepatic cholangiocarcinoma.

Authors:  Rei Okada; Hideaki Shimada; Yuichiro Otsuka; Masaru Tsuchiya; Jun Ishii; Toshio Katagiri; Tetsuya Maeda; Yoshihisa Kubota; Tetsuo Nemoto; Hironori Kaneko
Journal:  Surg Today       Date:  2017-05-15       Impact factor: 2.549

Review 4.  [Treatment approach for gall bladder and extrahepatic bile duct cancer].

Authors:  S Manekeller; J C Kalff
Journal:  Chirurg       Date:  2018-11       Impact factor: 0.955

5.  Over 700 Whipples for Pancreaticobiliary Malignancies: Postoperative Morbidity Is an Additional Negative Prognostic Factor for Distal Bile Duct Cancer.

Authors:  Stefano Andrianello; Giovanni Marchegiani; Giuseppe Malleo; Borislav Chavdarov Rusev; Aldo Scarpa; Deborah Bonamini; Laura Maggino; Claudio Bassi; Roberto Salvia
Journal:  J Gastrointest Surg       Date:  2016-11-23       Impact factor: 3.452

6.  Preoperative Cholangitis Affects Survival Outcome in Patients with Extrahepatic Bile Duct Cancer.

Authors:  Masayuki Akita; Tetsuo Ajiki; Taku Matsumoto; Kenta Shinozaki; Tadahiro Goto; Sadaki Asari; Hirochika Toyama; Masahiro Kido; Takumi Fukumoto; Yonson Ku
Journal:  J Gastrointest Surg       Date:  2017-03-13       Impact factor: 3.452

7.  Development and external validation of a prediction model for overall survival after resection of distal cholangiocarcinoma.

Authors:  Ali Belkouz; Stijn Van Roessel; Marin Strijker; Jacob L van Dam; Lois Daamen; Lydia G van der Geest; Alberto Balduzzi; Andrea Benedetti Cacciaguerra; Susan van Dieren; Quintus Molenaar; Bas Groot Koerkamp; Joanne Verheij; Elizabeth Van Eycken; Giuseppe Malleo; Mohammed Abu Hilal; Martijn G H van Oijen; Ivan Borbath; Chris Verslype; Cornelis J A Punt; Marc G Besselink; Heinz-Josef Klümpen
Journal:  Br J Cancer       Date:  2022-01-17       Impact factor: 9.075

Review 8.  A review of systemic therapy in biliary tract carcinoma.

Authors:  Holger Jansen; Ulrich-Frank Pape; Nalân Utku
Journal:  J Gastrointest Oncol       Date:  2020-08

9.  Predictors of postoperative early recurrence of extrahepatic bile duct cancer.

Authors:  Masayuki Akita; Tetsuo Ajiki; Kimihiko Ueno; Daisuke Tsugawa; Yu Hashimoto; Motofumi Tanaka; Masahiro Kido; Hirochika Toyama; Takumi Fukumoto
Journal:  Surg Today       Date:  2019-09-23       Impact factor: 2.549

10.  Surgical management of biliary malignancy.

Authors:  T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica
Journal:  Curr Probl Surg       Date:  2020-06-30       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.